US EditionGC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine
- In April 2025, the MFDS approved BARYTHRAX, an anthrax vaccine developed by GC Biopharma and KDCA.
- Anthrax poses a bioweapon threat, and without treatment, the fatality rate could reach 97%.
- BARYTHRAX, the 39th novel drug in Korea, is the first recombinant protein anthrax vaccine globally.
- During Phase II trials, subjects showed sufficient antibody generation and reported no severe adverse events.
- GC Biopharma's capacity and the MFDS approval allow it to supply Korea's essential anthrax vaccine.
38 Articles
38 Articles
South Korea unveils world’s first recombinant anthrax vaccine to combat bioterrorism threats
South Korea approved the world’s first genetically engineered anthrax vaccine, which significantly reduces toxin-related side effects compared to earlier versions. The Korea Disease Control and Preven...
Rutland Herald
GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine
YONGIN, South Korea, April 9, 2025 /PRNewswire/ -- GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly developed by GC Biopharma and the Korea Disease Control…
GC Biopharma Receives MFDS Approval for World’s First Recombinant Anthrax Vaccine
YONGIN, South Korea, April 9, 2025 /PRNewswire/ — GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA). With the approval by MFDS, BARYTHRAX has become Korea’s 39th novel […]
Coverage Details
Bias Distribution
- 50% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
